Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features

Cancer Research

Volumn 73, Issue 11, 2013, Pages 3297-3305

  Liu, Qingxin ^a   Russell, Mike R ^c   Shahriari, Kristina ^a   Jernigan, Danielle L ^a   Lioni, Mercedes I ^a   Garcia, Fernando U ^a   Fatatis, Alessandro ^a,b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELAFIN; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 1BETA; PROSTATE SPECIFIC ANTIGEN; SYNAPTOPHYSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; CXCL6 GENE; CYTOKINE RELEASE; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLEASON SCORE; HUMAN; HUMAN CELL; IL 1BETA GENE; IMMUNODETECTION; MALE; METASTASIS POTENTIAL; MOUSE; NEUROENDOCRINOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PI3 GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; TISSUE MICROARRAY;

ADENOCARCINOMA; ANIMALS; BONE NEOPLASMS; CARCINOMA, NEUROENDOCRINE; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; IMMUNOCOMPROMISED HOST; INTERLEUKIN-1BETA; MALE; MICE; NEUROENDOCRINE CELLS; NIH 3T3 CELLS; PROSTATIC NEOPLASMS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SYNAPTOPHYSIN; UP-REGULATION;

EID: 84878551352     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3970     Document Type: Article

References (54)

1. MoulJW, EvansCP, GomellaLG, RoachM, DreicerR. Traditional approaches to androgen deprivation therapy. Urology 2011;78:S485-93.
2. Kelly WK, Gomella LG. Androgen deprivation therapy and competing risks. JAMA 2011;306:2382-3.
3. Attard G, Reid AHM, Olmos D, de Bono JS. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009;69:4937-40.
4. Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010;21:315-24.
5. Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. Dent P editor. PLoS ONE 2011;6:e19059.
6. Debes JD, Tindall DJ. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 2002;187:1-7.
7. Yang JC, Ok J-H, Busby JE, Borowsky AD, Kung H-J, Evans CP. Aberrant activation of androgen receptor in a new neuropeptideautocrine model of androgen-insensitive prostate cancer. Cancer Res 2009;69:151-60.
8. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011;1:487-95.
9. Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. Am J Transl Res 2009;1:148-62.
10. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998;51: 585-9.
11. Puccetti L, Supuran CT, Fasolo PP, Conti E, Sebastiani G, Lacquaniti S, et al. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. Eur Urol 2005;48:215-21.
12. Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, et al. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 2002;95: 1028-36.
13. Dolloff NG, Shulby SS, Nelson AV, Stearns ME, Johannes GJ, Thomas JD, et al. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor. Oncogene 2005;24:6848-54.
14. Russell MR, Jamieson WL, Dolloff NG, Fatatis A. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene 2009;28:412-21.
15. Russell MR, Liu Q, Lei H, Kazlauskas A, Fatatis A. The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand-and dimerization-independent mechanisms. Cancer Res 2010;70:4195-203.
16. Wang M, Stearns ME. Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice. Differentiation 1991;48:115-25.
17. Masters Jr. Human cancer cell lines: fact and fantasy. Nat Rev Mol Cell Biol 2000;1:233-6.
18. Jamieson WL, Shimizu S, D'Ambrosio JA, Meucci O, Fatatis A. CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res 2008;68:1715-22.
19. Li H-J, Reinhardt F, Herschman HR, Weinberg RA. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov 2012;2:840-55.
20. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
21. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
22. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang C-Z, et al. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate 2011;71:1668-79.
23. Russell MR, Liu Q, Fatatis A. Targeting the {alpha} receptor for plateletderived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clin Cancer Res 2010;16:5002-10.
24. Mickey DD, Stone KR, Wunderli H, Mickey GH, Vollmer RT, Paulson DF. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res 1977;37:4049-58.
25. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU145). Int JCancer 1978;21:274-81.
26. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 2006;107:1265-72.
27. Yigitbasi O, Ozturk U, Goktug HNG, Gucuk A, Bakirtas H. Prognostic factors in metastatic prostate cancer. Urol Oncol 2011;29:162-5.
28. Abdul M, Hoosein N. Differences in the expression and effects of interleukin-1 and -2 on androgen-sensitive and -insensitive human prostate cancer cell lines. Cancer Lett 2000;149:37-42.
29. Culig Z, Klocker H, Bartsch G, Hobisch A. Androgen receptors in prostate cancer. Endocr Relat Cancer 2002;9:155-70.
30. Vashchenko N, Abrahamsson P-A. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005;47:147-55.
31. Yin J, Pollock C, Tracy K, Chock M, Martin P, Oberst M, et al. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol 2007;27:7538-50.
32. Hoosein NM. Neuroendocrine and immune mediators in prostate cancer progression. Front Biosci 1998;3:D1274-9.
33. Leiblich A, Cross SS, Catto JWF, Pesce G, Hamdy FC, Rehman I. Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. Prostate 2007;67:1761-9.
34. Miyoshi Y, Uemura H, Kitami K, Satomi Y, Kubota Y, Hosaka M. Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int 2001;88:982-3.
35. Frigo DE, McDonnell DP. Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol Cancer Ther 2008;7:659-69.
36. Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA, et al. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 2007;9:938-50.
37. Shibue T, Weinberg RA. Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin Cancer Biol 2011;21:99-106.
38. Weilbaecher KN, Guise TA, Mccauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11:411-25.
39. Evans DB, Bunning RA, Russell RG. The effects of recombinant human interleukin-1 beta on cellular proliferation and the production of prostaglandin E2, plasminogen activator, osteocalcin and alkaline phosphatase by osteoblast-like cells derived from human bone. Biochem Biophys Res Commun 1990;166:208-16.
40. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011;8:357-68.
41. Higano CS. New treatment options for patients with metastatic castration-resistant prostate cancer. Cancer Treat Rev 2012;38:340-5.
42. Vukmirovic-Popovic S, Colterjohn N, Lhoták S, Duivenvoorden WCM, Orr FW, Singh G. Morphological, histomorphometric, and microstructural alterations in human bone metastasis from breast carcinoma. Bone 2002;31:529-35.
43. Lee Y, Schwarz E, Davies M, Jo M, Gates J, Wu J, et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 2006;21: 62-72.
44. Schulze J, Weber K, Baranowsky A, Streichert T, Lange T, Spiro AS, et al. p65-Dependent production of interleukin-1b by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts. Cancer Lett 2012;317:106-13.
45. Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633-52.
46. Kim M-Y, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH-F, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell 2009;139:1315-26.
47. Lin H, Balic M, Zheng S, Datar R, Cote RJ. Disseminated and circulating tumor cells: Role in effective cancer management. Crit Rev Oncol Hematol 2011;77:1-11.
48. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. Chin W-C editor. PLoS ONE 2012;7:e33788.
49. Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models inmice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008;10: R67.
50. Cardiel MH, Tak PP, Bensen W, Burch FX, Forejtova S, Badurski JE, et al. A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis. Arthritis Res Ther 2010;12:R192.
51. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
52. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
53. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22: 2790-9.
54. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9.